使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2013 earnings release conference call. (Operator Instructions). And as a reminder, this conference is being recorded.
各位女士、先生,感謝您稍候,歡迎參加直覺外科(Intuitive Surgical)2013 年第二季財報發布電話會議。(接線員指示)。提醒各位,本次會議將被錄音。
I would now like to turn the conference over to our host, Calvin Darling, Senior Director of Finance for Intuitive Surgical. Please go ahead, sir.
現在我想把會議交給我們的主持人——直覺外科財務資深總監 Calvin Darling。先生,請開始。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you. Good afternoon and welcome to Intuitive Surgical's second-quarter earnings conference call. With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.
謝謝。各位下午好,歡迎參加直覺外科第二季財報電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及策略規劃副總裁 Aleks Cukic。
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties.
在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。
These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission's filings, including our most recent Form 10-K filed on February 4, 2013; and our Form 10-Q filed on April 19, 2013. These filings can be found through our website or at the SEC's Edgar database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳述,包括我們於 2013 年 2 月 4 日提交的最新 Form 10-K,以及於 2013 年 4 月 19 日提交的 Form 10-Q。這些文件可透過我們的網站或 SEC 的 Edgar 資料庫查閱。提醒潛在投資人勿過度依賴此類前瞻性陳述。
Please note that this conference call will be available for audio replay on our website at IntuitiveSurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release has been posted to our website.
請注意,本次電話會議的音訊重播將可於我們網站 IntuitiveSurgical.com 的投資人關係頁面下之 Audio Archives 區域收聽。此外,今天的新聞稿也已發布於我們的網站。
Today's format will consist of providing you with the highlights of our second-quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second-quarter financial results. Aleks will discuss marketing and clinical highlights; then I will provide an update to our financial forecast for 2013. And finally, we will host a question-and-answer session.
今天的流程將先提供我們第二季業績重點(如稍早發布之新聞稿所述),接著進行問答。Gary 將介紹本季的業務與營運重點。Marshall 將回顧我們第二季的財務結果。Aleks 將討論行銷與臨床重點;接著我將更新我們對 2013 年的財務預測。最後,我們將進行問答環節。
With that, I'll turn it over to Gary.
接下來交給 Gary。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you for joining us today. As we previously announced, our second quarter has been a challenging one. Capital sales fell 5% from the prior year, with the shortfall concentrated in United States. We attribute the miss primarily to slower-than-expected da Vinci benign gynecology procedure growth in the United States. Taken globally, overall procedure performance in the quarter was solid, rising 18% over prior year in the face of several headwinds.
感謝各位今天加入我們。如我們先前所宣布的,第二季對我們而言相當具挑戰性。資本設備銷售較去年同期下滑 5%,缺口主要集中在美國。我們將未達預期主要歸因於美國達文西(da Vinci)良性婦科手術量成長低於預期。從全球來看,儘管面臨多項逆風,本季整體手術量表現仍然穩健,較去年同期成長 18%。
Summarizing procedures in the United States, strong general surgery growth continued, centered within Single-Site cholecystectomy and colorectal resections.
概述美國的手術量情況:一般外科的強勁成長持續,主要集中在單孔(Single-Site)膽囊切除術與結直腸切除手術。
In gynecology, dVH for malignant conditions was solid, while dVH growth for benign indications grew more slowly than expected. Urologic procedures continued to be stable.
在婦科方面,針對惡性疾病的 dVH 表現穩健,而針對良性適應症的 dVH 成長則低於預期。泌尿科手術量持續保持穩定。
In Europe, procedures grew sequentially over Q1, led by urology and early growth in malignant dVH. Growth was strongest in the UK and Nordic countries, moderate in the core countries, and weakest in the South. Procedure growth in Asia was strong off of a small base, led by growth in urology in general surgery, with particular strength in Japan, Taiwan, and China.
在歐洲,手術量較第一季呈現季增,主要由泌尿科以及惡性 dVH 的早期成長帶動。成長最強勁的是英國與北歐國家;核心國家成長中等;南歐最為疲弱。亞洲的手術量在較小基期上呈現強勁成長,主要由泌尿科與一般外科的成長帶動,其中以日本、台灣與中國表現尤為突出。
Turning to systems, we sold 143 systems -- 7 fewer than Q2 of 2012 -- with sales of new systems in the United States totaling 90, down from 124 a year ago. We believe the slowing of our growth in benign gynecologic procedures in the United States to be a significant contributor to weaker-than-expected system sales.
談到系統銷售,我們售出 143 套系統——較 2012 年第二季少 7 套——其中美國新系統銷售合計 90 套,低於一年前的 124 套。我們認為,美國良性婦科手術成長放緩,是系統銷售弱於預期的重要因素。
There appear to be a couple of underlying causes for slower-than-expected US benign dVH growth. Overall admissions for benign gynecology appear to be under pressure in the first half of 2013. Since we are a significant share of hysterectomy, our growth rate in dVH is sensitive to these admissions.
美國良性 dVH 成長低於預期,似乎有幾個根本原因。2013 年上半年,良性婦科的整體住院量似乎承受壓力。由於我們在子宮切除術中占有相當高的比重,dVH 的成長率對這些住院量變化相當敏感。
Second, our MCS notification and negative press occurred in the quarter and may have pressured growth in utilization, although estimating their impact on procedure volume is difficult. Given that the average da Vinci system is used for hundreds of procedures per year, a change in da Vinci patient admissions can free capacity on existing systems and pressure new system sales. This appears to be the case this quarter. Looking toward the second half of the year, we see increasing pressure on US system sales.
第二,我們在本季發布 MCS 通知並出現負面媒體報導,可能對使用率成長造成壓力,然而要估計其對手術量的影響並不容易。鑑於平均每套達文西系統每年可用於數百例手術,達文西病患入院量的變化可能釋放既有系統的產能,並對新系統銷售造成壓力。本季似乎正是如此。展望下半年,我們看到美國系統銷售面臨更大的壓力。
Globally, our business in Asia has continued to build. In Japan system sales were strong in the quarter, showing continued interest in da Vinci surgery. Our work with surgical societies is ongoing in their efforts to obtain national reimbursement for procedures beyond prostatectomy. Currently it appears unlikely that additional procedures will receive national reimbursement in the April 2014 insurance revision, given recent guidance from MHLW.
在全球方面,我們在亞洲的業務持續擴展。日本本季系統銷售強勁,顯示市場對達文西手術的興趣持續。我們與外科醫學會的合作仍在進行中,協助其爭取前列腺切除術以外手術的全國性給付。根據日本厚生勞動省(MHLW)近期的指引,目前看來在 2014 年 4 月的保險修訂中,其他手術獲得全國性給付的可能性不高。
As we have said in the past, we continue to expect Japan system sales to be highly variable from quarter to quarter. We are investing in building our team in Japan with a view towards long-term performance.
如同我們過去所說,我們仍預期日本的系統銷售將在各季度之間高度波動。我們正投資擴建日本團隊,以著眼於長期表現。
Capital sales in Europe have grown over the past few quarters in a difficult environment. As we've said on prior calls, sales force changes in Europe have made a positive difference. We're gathering European clinical and reimbursement data and expect these investments to increase in the future. Given macroeconomic stresses in Europe and government processes, we expect reimbursement efforts to be a long-term endeavor.
在艱困的環境下,歐洲的資本設備銷售在過去幾個季度有所成長。如同我們在先前電話會議所提到的,歐洲銷售團隊的調整帶來了正面差異。我們正在蒐集歐洲的臨床與給付資料,並預期未來將增加這些投資。考量歐洲的總體經濟壓力與政府流程,我們預期給付推動將是一項長期工作。
During the quarter FDA conducted an on-site audit of ISI and issued a set of 4 observations in a Form 483, previously reported in June. Yesterday we received a warning letter from the FDA as a follow-on to these audit inspection findings, asking for additional steps to resolve 2 of the observations. These concerns are addressable, and we are in the process of doing so.
本季 FDA 對 ISI 進行了現場稽核,並在 Form 483 中提出 4 項觀察事項,我們已於 6 月先前報告。昨日,我們收到 FDA 的警告信,作為上述稽核檢查發現的後續,要求我們採取額外步驟以解決其中 2 項觀察事項。這些疑慮是可以處理的,我們正著手進行。
Turning to operating performance for the second quarter, procedures grew approximately 18% over the second quarter of 2012. We sold 143 da Vinci Surgical Systems, down from 150 during the second quarter of last year.
回到第二季的營運表現,手術量較 2012 年第二季約成長 18%。我們售出 143 套達文西手術系統,低於去年第二季的 150 套。
Total revenue was $579 million, up 8% over last year. Instrument and accessory revenue increased to $265 million, up 18% over Q2 2012. Total recurring revenue grew to $363 million, up 18% from prior year and comprising 63% of total revenue.
總營收為 5.79 億美元,較去年成長 8%。器械與配件營收增至 2.65 億美元,較 2012 年第二季成長 18%。總經常性營收增至 3.63 億美元,較去年同期成長 18%,占總營收的 63%。
Net income was $159 million, up 3% over last year. And we generated an operating profit of $257 million before noncash stock option expense, down 1% from the second quarter of last year and representing 45% of Q2 revenue.
淨利為 1.59 億美元,較去年成長 3%。在扣除非現金股票選擇權費用之前,我們產生的營業利益為 2.57 億美元,較去年第二季下滑 1%,相當於第二季營收的 45%。
We ended the quarter with $3.270 billion in cash and investments, down $89 million from last quarter. In the quarter we generated $189 million in gross cash flow from operations, which is 119% of our reported GAAP net income. And finally, we repurchased $270 million of our stock.
本季結束時,我們持有的現金與投資為 32.70 億美元,較上季減少 8,900 萬美元。本季我們自營運產生的毛現金流為 1.89 億美元,為我們所報告 GAAP 淨利的 119%。最後,我們回購了 2.70 億美元的公司股票。
Before turning the time over to Marshall, it's worth taking a step back and looking at a longer-term view of da Vinci technology in surgery. We remain deeply positive on the value da Vinci can bring to surgery now and in the future. The benefit da Vinci brings as an alternative to open surgery has been demonstrated in hundreds of the peer-reviewed clinical papers and is widely accepted by our customers. As some da Vinci procedures mature in the United States, we are increasingly exposed to volatility in patient admissions for our core procedures and the consequent lumpiness in capital sales.
在把時間交給 Marshall 之前,值得先退一步,從更長期的角度來看達文西(da Vinci)技術在外科手術中的發展。我們對達文西目前及未來能為外科手術帶來的價值,仍然抱持高度正面的看法。達文西作為傳統開放式手術替代方案所帶來的效益,已在數百篇同儕審查的臨床論文中獲得證實,並廣為我們的客戶所接受。隨著部分達文西手術在美國逐漸成熟,我們在核心手術的病患入院量上愈來愈暴露於波動之中,並因此使資本設備銷售呈現更不均勻的起伏。
Viewed over the long term, da Vinci surgery contributes to a trend in surgery toward consolidation of procedures and to fewer surgeons with higher volume. We believe this consolidation is good for patients, surgeons, hospitals, and Intuitive.
從長期來看,達文西手術促成外科領域朝向手術整合的趨勢,並使外科醫師人數減少、但每位醫師的手術量提高。我們相信,這種整合對病患、外科醫師、醫院以及 Intuitive 都是有利的。
We are still early in the global adoption of da Vinci-enabled minimally invasive surgery as applied to complex conditions. In recent quarters we have seen building interest in the use of da Vinci in general surgery, spanning procedures from the pelvis to the upper gastrointestinal tract.
在全球採用達文西輔助的微創手術、並將其應用於複雜病症方面,我們仍處於早期階段。近幾季我們看到外界對在一般外科使用達文西的興趣正在升溫,涵蓋從骨盆到上消化道的多種手術。
As we expand our offerings in technologies like vessel sealing, stapling, and Firefly, we are seeing increased utilization and efficiency in general surgery procedures that are otherwise very difficult to perform. Taking a recent example, EndoWrist Vessel Sealers are now installed in roughly half of our US customers. These technologies also open the door to additional clinical applications such as thoracic surgery, where long-term additions to stapling can bring benefit to procedures that are often difficult to perform through small incisions.
隨著我們擴充如血管封合、縫合釘合(stapling)以及 Firefly 等技術的產品供應,我們看到在一般外科手術中,對於原本非常難以執行的手術,其使用率與效率均有所提升。以近期例子而言,EndoWrist 血管封合器目前已安裝於約一半的美國客戶。這些技術也為額外的臨床應用打開大門,例如胸腔外科;在該領域,長期在釘合技術上的增補可為那些通常難以透過小切口完成的手術帶來效益。
Looking at single-incision surgery, Single-Site cholecystectomy kits have been purchased by approximately half of our US customers 18 months after launch. This procedure is currently growing faster than any prior da Vinci procedure. Early-adopting clinical sites have been progressing in refining procedure choreography with Single-Site hysterectomy, as well.
就單切口手術而言,Single-Site 膽囊切除術套件在上市 18 個月後,約有一半的美國客戶已購買。此項手術目前的成長速度快於以往任何一項達文西手術。早期採用的臨床據點也在 Single-Site 子宮切除術方面,持續精進手術流程編排。
Furthermore, we are investing in expanding Single-Site technology and expect to bring to market additional Single-Site instruments as well as integration with other da Vinci technologies, including Firefly and simulation. As our product suite develops further, we anticipate pursuing additional clinical indications for Single-Site.
此外,我們正投資擴充 Single-Site 技術,並預期將推出更多 Single-Site 器械,同時與其他達文西技術整合,包括 Firefly 與模擬系統。隨著我們的產品組合進一步發展,我們預期將為 Single-Site 追求更多臨床適應症。
Considering trends in healthcare policy around the globe, a long-term intention to move away from fee-for-service and towards single payment per treatment event can advantage those approaches with fewer complications and fewer readmissions. Also, the trend toward public transparency of individual surgeon and hospital outcomes has potential to shift patient dynamics toward those programs showing the best outcomes. Again, while we cannot predict future implementations of policy, we believe their direction may set up well for da Vinci surgeons, their patients, and hospital programs.
考量全球醫療政策的趨勢,長期而言,從按服務計費(fee-for-service)轉向每次治療事件單一支付的意圖,可能使那些併發症較少、再入院率較低的治療方式更具優勢。此外,朝向公開透明揭露個別外科醫師與醫院治療結果的趨勢,可能使病患選擇動態轉向那些展現最佳結果的醫療計畫。同樣地,雖然我們無法預測未來政策的具體落地方式,但我們相信其方向可能有利於達文西外科醫師、其病患以及醫院的相關計畫。
In summary, we continue to see a long-term opportunity to fundamentally improve surgery and are focused on the following -- extending the benefits of minimally invasive surgery using da Vinci in gynecology and urology worldwide; building da Vinci capability and supporting its use in general surgery; disciplined execution in our stapling and Single-Site product launches; and finally, continuing to invest in our capabilities in international markets, particularly Europe and Japan.
總結而言,我們仍看到一個長期機會,能從根本上改善外科手術,並聚焦於以下幾點——在全球婦科與泌尿科領域,運用達文西延伸微創手術的效益;建立達文西在一般外科的能力並支持其使用;在釘合與 Single-Site 產品上市方面嚴謹執行;最後,持續投資我們在國際市場的能力,特別是歐洲與日本。
I will now pass the time over to Marshall, our Chief Financial Officer.
現在我把時間交給我們的財務長 Marshall。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Thank you, Gary. Our second-quarter revenue was $579 million, up 8% compared with $537 million for the second quarter of 2012, and down 5% from last quarter. Second-quarter revenues by product category were as follows -- second-quarter instrument and accessory revenue was $265 million, up 18% compared with $224 million for the second quarter of 2012 and up 1% compared with the first quarter of 2013.
謝謝你,Gary。我們第二季營收為 5.79 億美元,較 2012 年第二季的 5.37 億美元成長 8%,較上一季下降 5%。第二季依產品類別的營收如下——第二季器械與配件營收為 2.65 億美元,較 2012 年第二季的 2.24 億美元成長 18%,較 2013 年第一季成長 1%。
The year-over-year increase in instrument and accessory revenue was driven by procedure growth of 18%. Sales of new products, including Single-Site, Vessel Sealer, and Firefly, partially offset by lower instrument and accessory stocking orders associated with lower second quarter systems sales.
器械與配件營收的年增主要由 18% 的手術量成長所帶動。新產品的銷售(包括 Single-Site、血管封合器與 Firefly)帶來部分抵銷,但也受到與第二季系統銷售較低相關的器械與配件初始備貨訂單減少所影響。
The 18% increase in da Vinci procedures for the quarter reflected strength in general surgery procedures and slower growth in benign gynecologic procedures. As Gary indicated, the slowdown in benign gynecologic growth reflects a number of factors including but not limited to weaker hospital admissions for benign da Vinci procedures.
本季達文西手術量成長 18%,反映一般外科手術表現強勁,以及良性婦科手術成長較慢。如 Gary 所指出,良性婦科成長放緩反映多項因素,包括但不限於良性達文西手術的醫院收治(入院)量較弱。
Our second-quarter 2013 US dVP procedures were approximately 5% lower than the second quarter of 2012 and 2% lower than the first quarter of 2013. The sequential increase in instrument and accessory revenue compared with last quarter was driven by higher procedure volume, partially offset by lower instrument and accessory stocking orders.
我們 2013 年第二季美國 dVP 手術量約較 2012 年第二季低 5%,較 2013 年第一季低 2%。與上一季相比,器械與配件營收的季增主要由較高的手術量所帶動,但部分被較低的器械與配件初始備貨訂單所抵銷。
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $2,020 per procedure, which was roughly equal to the second quarter 2012 and lower than the approximately $2,110 last quarter. The decrease compared to the first quarter reflected lower stocking orders and the timing of orders.
每例手術實現的器械與配件營收(包含初始備貨訂單)約為每例 2,020 美元,與 2012 年第二季大致相當,且低於上一季約每例 2,110 美元。相較第一季的下降,反映初始備貨訂單較少以及訂單時點的影響。
Second-quarter 2013 systems revenue of $216 million decreased 6% compared with $229 million for the second quarter of 2012, and decreased 16% compared with $256 million last quarter. Overall, we sold 143 systems in the second quarter of 2013 compared with 150 systems in the second quarter of last year and 164 systems last quarter.
2013 年第二季系統營收為 2.16 億美元,較 2012 年第二季的 2.29 億美元下降 6%,較上一季的 2.56 億美元下降 16%。整體而言,我們在 2013 年第二季售出 143 套系統,對比去年第二季 150 套,以及上一季 164 套。
We sold 90 systems into the US market in the second quarter of 2013 compared with 124 systems last year and 115 systems last quarter. The lower second quarter 2013 US systems sales reflected, among other things, the impacts of moderating growth in US benign gynecologic procedures and increased economic pressure on hospitals.
2013 年第二季我們在美國市場售出 90 套系統,對比去年 124 套,以及上一季 115 套。2013 年第二季美國系統銷售較低,反映了多項因素,其中包括美國良性婦科手術成長趨緩,以及醫院面臨更大的經濟壓力。
During the second quarter of 2013 we sold 53 systems into international markets, including 21 into Europe and 20 into Japan. Compared with 26 in international markets in the second quarter of 2012, which included 13 into Europe and 7 into Japan; and 49 systems in international markets in the first quarter of 2013, which included 16 into Europe and 25 into Japan.
2013 年第二季我們在國際市場售出 53 套系統,其中包括歐洲 21 套、日本 20 套。相較之下,2012 年第二季國際市場為 26 套,其中歐洲 13 套、日本 7 套;而 2013 年第一季國際市場為 49 套,其中歐洲 16 套、日本 25 套。
Our second-quarter average sales price per system was $1.5 million compared with $1.53 million realized in the second quarter of 2012 and the $1.55 million realized last quarter. ASPs include all da Vinci models, all simulators, and Firefly when configured with a system, and exclude upgrades.
我們第二季每套系統的平均銷售價格為 150 萬美元,對比 2012 年第二季實現的 153 萬美元,以及上一季實現的 155 萬美元。平均銷售價格(ASP)包含所有達文西機型、所有模擬器,以及系統配置時的 Firefly,並排除升級(upgrade)。
Our second-quarter 2013 ASPs were lower than the first quarter due to a lower proportion of dual-console configurations and slightly higher proportion of sales involving trade-ins. 43 of our second-quarter 2013 systems sales involved trade-ins, comprised of 39 da Vinci Ss and 4 standard models. 35 of our second quarter 2012 sales involved trade-ins, and 39 of our first-quarter 2013 sales involved trade-ins.
我們 2013 年第二季 ASP 低於第一季,原因在於雙控制台配置的占比較低,以及涉及以舊換新(trade-in)的銷售占比略高。2013 年第二季的系統銷售中,有 43 套涉及以舊換新,其中包含 39 套 da Vinci S 以及 4 套標準機型。2012 年第二季有 35 套銷售涉及以舊換新,而 2013 年第一季有 39 套銷售涉及以舊換新。
Service revenue increased to $98 million, up 18% compared with $83 million last year and up 4% compared with $94 million last quarter. The growth in service revenue was primarily driven by a larger system installed base.
服務營收增至 9,800 萬美元,較去年 8,300 萬美元成長 18%,較上一季 9,400 萬美元成長 4%。服務營收的成長主要由更大的系統裝機基數所帶動。
International revenue results were as follows. Second-quarter revenue outside the US was $158 million, up 56% compared with revenue of $101 million in the second quarter of last year, and up 3% compared with $153 million last quarter.
國際營收結果如下。第二季美國以外的營收為 1.58 億美元,較去年第二季的 1.01 億美元成長 56%,較上一季的 1.53 億美元成長 3%。
Our higher year-over-year international revenue growth was driven primarily by higher da Vinci systems sales into the Japanese and European markets. Our higher sequential international revenue was driven by higher European systems sales, partially offset by lower systems sales into Japan. The second-quarter 2013 international procedure volume was approximately 23% higher than the second quarter of 2012 and 6% higher than the first quarter of this year.
我們國際營收年增率較高,主要是因為日本與歐洲市場的 da Vinci 系統銷售增加所帶動。我們國際營收的季增,主要由歐洲系統銷售增加所驅動,但部分被日本系統銷售下降所抵銷。2013 年第二季的國際手術量約較 2012 年第二季高出 23%,並較今年第一季高出 6%。
Moving on to the remainder of the P&L, gross margin in the second quarter of 2013 was 70% compared with 72% for the second quarter of 2012 and 71% for the first quarter of 2013. Our lower margin percentage compared to the second quarter of last year resulted primarily from the impact of the Medical Device Excise Tax enacted beginning in 2013 and product mix. Our lower gross margin percentage compared to last quarter was driven primarily by costs associated with the MCS recall, lower system ASPs, and product mix.
接著談損益表其餘部分,2013 年第二季毛利率為 70%,相較於 2012 年第二季的 72% 以及 2013 年第一季的 71%。我們相較去年第二季毛利率較低,主要是因 2013 年起實施的醫療器材消費稅(Medical Device Excise Tax)影響以及產品組合所致。我們相較上季毛利率較低,主要由 MCS 召回相關成本、系統平均售價(ASP)較低以及產品組合所驅動。
Second-quarter 2013 operating expenses of $187 million were up 16% compared with the second quarter of 2012 and up 2% compared with the first quarter of this year. Our higher year-over-year operating expense increase was driven by headcount additions. Our increase compared to last quarter was driven by headcount additions and higher legal costs, offset by lower incentive compensation.
2013 年第二季營業費用為 1.87 億美元,較 2012 年第二季增加 16%,較今年第一季增加 2%。我們年增的營業費用上升,主要由人員編制增加所帶動。我們相較上季的增加,主要由人員編制增加與法律費用較高所致,但部分被較低的獎勵性薪酬所抵銷。
Second-quarter 2013 operating income was $219 million or 38% of sales, compared with $225 million or 42% of sales last year, and $251 million or 41% of sales last quarter. Second-quarter 2013 operating income included $39 million of noncash stock compensation expense, compared with $33 million last year and $38 million last quarter.
2013 年第二季營業利益為 2.19 億美元,或占銷售額 38%,相較去年為 2.25 億美元或占銷售額 42%,上季為 2.51 億美元或占銷售額 41%。2013 年第二季營業利益包含 3,900 萬美元的非現金股票薪酬費用,相較去年為 3,300 萬美元、上季為 3,800 萬美元。
Our effective tax rate for the second quarter was 28.6% compared with 32.4% for the second quarter of 2012 and 26.1% last quarter. Our second-quarter rate was a bit lower than the midpoint of our 28% to 30% guidance range, primarily reflecting a higher proportion of international pretax income.
我們第二季有效稅率為 28.6%,相較 2012 年第二季為 32.4%,上季為 26.1%。我們第二季稅率略低於 28% 至 30% 指引區間的中點,主要反映國際稅前所得占比提高。
Our net income was $159 million or $3.90 per share, compared with $155 million or $3.75 per share last year, and $189 million or $4.56 last quarter.
我們淨利為 1.59 億美元,或每股 3.90 美元,相較去年為 1.55 億美元或每股 3.75 美元,上季為 1.89 億美元或每股 4.56 美元。
Now moving to cash flows. We ended the second quarter with cash and investments of $3 billion, down $89 million compared with March 31, 2013. The decrease was driven by $270 million used to repurchase our common stock and $25 million of capital and IP acquisition, partially offset by $189 million in cash flow generated from operations.
接著談現金流。我們在第二季末的現金與投資為 30 億美元,較 2013 年 3 月 31 日減少 8,900 萬美元。下降主要因為用於回購普通股的 2.70 億美元,以及 2,500 萬美元的資本支出與智慧財產(IP)收購;部分被營運活動產生的 1.89 億美元現金流所抵銷。
During the second quarter we bought back approximately 546,000 shares at an average price of $493 per share. We ended the quarter with approximately $900 million authorized by the Board for share buybacks.
第二季期間,我們以每股平均 493 美元的價格回購約 546,000 股。本季結束時,董事會核准可用於股票回購的額度約為 9 億美元。
And with that, I'd like to turn it over to Aleks, who will go over our sales, marketing, and clinical highlights.
接下來,我想把時間交給 Aleks,他將說明我們的銷售、行銷與臨床重點。
Aleks Cukic - VP of Strategic Planning
Aleks Cukic - VP of Strategic Planning
Thank you, Marshall. During the second quarter we sold 143 da Vinci systems -- 90 in the United States, 21 into Europe, and 32 into rest of world markets. As part of the 143 systems sales, 4 standard da Vinci systems and 39 da Vinci S systems were traded in for credit against sales for new da Vinci Si systems.
謝謝你,Marshall。第二季我們共售出 143 套 da Vinci 系統——美國 90 套、歐洲 21 套、以及世界其他市場 32 套。在這 143 套系統銷售中,有 4 套標準 da Vinci 系統與 39 套 da Vinci S 系統以舊換新折抵,用於購買新的 da Vinci Si 系統。
We finished the quarter with a net 89 system additions to the installed base, bringing to 2,799 the cumulative number of da Vinci systems worldwide -- 2,001 in the United States, 443 in Europe, and 355 in rest of world markets. 61 of the 143 systems installed during the quarter represented repeat systems sales to existing customers.
本季我們的裝機基礎淨增加 89 套系統,使全球 da Vinci 系統累計數量達到 2,799 套——美國 2,001 套、歐洲 443 套、世界其他市場 355 套。本季安裝的 143 套系統中,有 61 套為既有客戶的重複購置。
In total, 140 of the 143 systems sold represented da Vinci Si or Si-e systems, which included 27 dual-console systems. The 53 systems sales internationally included 20 into Japan, 4 into Russia, and 3 into the countries of France, Germany, the UK, Australia, and Taiwan.
總計而言,售出的 143 套系統中有 140 套為 da Vinci Si 或 Si-e 系統,其中包含 27 套雙主控台系統。國際市場的 53 套系統銷售包括:日本 20 套、俄羅斯 4 套,以及法國、德國、英國、澳洲與台灣各 3 套。
Clinically, Q2 year-over-your procedure growth was approximately 18%, led by the category of general surgery, paced by cholecystectomy, followed by colorectal resections. Other general surgery procedures showing strong growth included gastric, pancreatic, and esophageal procedures. Overall, urology growth was solid and included strong OUS dVP growth, with continued stability in US dVP.
在臨床方面,第二季手術量年增約 18%,由一般外科類別領先,其中以膽囊切除術成長最快,其次為大腸直腸切除術。其他呈現強勁成長的一般外科手術還包括胃部、胰臟與食道手術。整體而言,泌尿科成長穩健,包含美國以外(OUS)的 dVP 強勁成長,同時美國 dVP 持續保持穩定。
As Gary stated, our benign GYN procedure growth moderated for the second quarter in a row, which had an adverse effect on our US systems sales. We believe that our US procedure opportunity within benign GYN remains solid, though we do recognize that the procedures remaining on the back half of the adoption curve will be more difficult to consolidate. The slower adoption within the benign GYN segment will most likely lead to continued lumpiness in US system placements.
如 Gary 所述,我們良性婦科(benign GYN)手術量成長已連續第二季趨緩,對我們美國系統銷售造成不利影響。我們認為在良性婦科領域,美國的手術機會仍然穩健,但也認知到採用曲線後半段所剩餘的手術將更難以整合。良性婦科區隔採用速度放緩,很可能導致美國系統裝機持續呈現不均勻(lumpiness)。
Recently-released new products continue to perform well. Through Q2 we've sold Single-Site instrument and accessory kits to approximately 740 US customers. Our Vessel Sealer product sales were strong, with most of the interest coming from the specialties of colorectal, advanced general, and GYN surgery.
近期推出的新產品持續表現良好。截至第二季,我們已向約 740 家美國客戶銷售 Single-Site 單孔器械與配件套組。我們的 Vessel Sealer 產品銷售強勁,且多數需求來自大腸直腸、進階一般外科與婦科手術等專科。
The customer adoption for both da Vinci Simulator and Firefly continues to expand, with 96 customers purchasing a da Vinci Simulator and 76 customers purchasing Firefly systems as part of their initial system purchase this quarter. In addition, we've expanded our phased rollout of both the da Vinci surgical stapling system and Single-Site hysterectomy products to several new sites. These rollouts will be expanded in a measured fashion, so we do not expect them to contribute materially to 2013 revenue.
da Vinci Simulator 與 Firefly 的客戶採用持續擴大,本季有 96 位客戶購買 da Vinci Simulator,另有 76 位客戶在首次購機時將 Firefly 系統納入採購。此外,我們也將 da Vinci 手術縫合釘系統與 Single-Site 子宮切除產品的分階段推廣擴展至數個新據點。這些推廣將以審慎方式逐步擴大,因此我們預期它們對 2013 年營收不會有重大貢獻。
During the quarter several hundred robotic abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals, while quarterly clinical conferences produced several live da Vinci procedure transmissions, postgraduate robotic courses, podium presentations, and clinical poster sessions. So I'll take a few moments to summarize a couple that provide interesting perspectives within the area of general surgery.
本季有數百篇與機器人手術相關的摘要與論文在各類同儕審查期刊發表,季度臨床會議亦進行了多場 da Vinci 手術的現場轉播、研究所後機器人課程、講台報告以及臨床海報展示。因此我將花幾分鐘摘要其中幾項,提供一般外科領域一些有趣的觀點。
The rate of surgical conversions from the laparoscopic procedure to an open surgery is most often related to the complexity of the procedure. We've described this relationship within our urologic and gynecologic procedure businesses and believe it applies to all surgical specialties in which we participate. This past quarter several peer-reviewed general surgery studies described da Vinci surgery within this very context.
手術從腹腔鏡轉為開腹手術的轉換率,多半與手術複雜度相關。我們已在泌尿科與婦科手術業務中描述過此一關係,並相信它適用於我們參與的所有外科專科。在過去一季中,數項經同儕審查的一般外科研究正是在此脈絡下描述 da Vinci 手術。
A colorectal study published in the journal Surgical Endoscopy compared 84 consecutive minimally-invasive, low-anterior resections, 47 incorporating da Vinci and 37 employing traditional laparoscopic technique. The study, emanating out of a division of colorectal surgery at Yonsei University Hospital, completed in 2010, had a median follow-up period of 31.5 months.
發表於《Surgical Endoscopy》的大腸直腸研究比較了 84 例連續的微創低位前切除術,其中 47 例採用 da Vinci,37 例採用傳統腹腔鏡技術。該研究由延世大學醫院(Yonsei University Hospital)的大腸直腸外科部門完成,於 2010 年結束,中位追蹤期為 31.5 個月。
Within their review the authors described overall safety and efficacy as similar within the 2 cohorts. However, the differences in the conversion rate from MIS to open and overall hospital stay were considered significant. Within the laparoscopic cohort, 16.2% of the patients had required conversions to open surgical technique as compared to 2.1% within the da Vinci cohort.
在其回顧中,作者指出兩個隊列的整體安全性與有效性相近。然而,從微創手術(MIS)轉為開腹手術的轉換率,以及整體住院天數的差異,被認為具有顯著性。在腹腔鏡隊列中,有 16.2% 的病患需要轉為開腹手術技術,相較之下 da Vinci 隊列為 2.1%。
Though both techniques are minimally invasive, the requisite hospitalization for patients undergoing a da Vinci colorectal resection was reduced by 2 days. The authors stated, and I quote, we compared the long- and short-term results for patients who underwent robotic and laparoscopic low-anterior resection and colo-anal anastomosis. Robotic colo-anal anastomosis had short- and long-term outcomes comparable with those of the laparoscopy.
雖然兩種技術皆屬微創,但接受達文西結直腸切除術的病患,其所需住院天數減少了2天。作者表示,我引用原文,我們比較了接受機器人與腹腔鏡低位前切除術及結腸-肛門吻合術病患的長期與短期結果。機器人結腸-肛門吻合術的短期與長期結果與腹腔鏡相當。
In particular, we found that patients in the robotic group demonstrated significantly lower rates of conversion to open surgery and had shorter hospital stay than the patients in the laparoscopic group. A low rate of conversion to open surgery has a very important impact clinically, because the conversions often are associated with high complication rate and a poor prognosis. End quote.
特別是,我們發現機器人組病患轉為開腹手術的比率顯著較低,且住院時間較腹腔鏡組病患更短。低轉開腹手術率在臨床上具有非常重要的影響,因為轉開腹往往與較高的併發症發生率及較差的預後相關。引文結束。
In the Annals of Surgery, a study conducted at the University of Pittsburgh, entitled Robotic-assisted Minimally Invasive Distal Pancreatectomy Is Superior to Laparoscopic Technique, compared the results of the department's first 30 da Vinci distal pancreatectomies to a historical cohort comprised of their last 94 laparoscopic distal pancreatectomies. The patients in the study demonstrated equivalent age, sex, race, ASA scores, and tumor size.
在《Annals of Surgery》上,匹茲堡大學進行的一項研究,題為《機器人輔助微創遠端胰臟切除術優於腹腔鏡技術》,比較了該科室前30例達文西遠端胰臟切除術的結果,與一個歷史對照隊列(由其最後94例腹腔鏡遠端胰臟切除術組成)。研究中的病患在年齡、性別、種族、ASA評分及腫瘤大小方面相當。
Within their comments, the authors noted to their surprise that the operating time between the 2 cohorts showed a substantial reduction of over 75 minutes in favor of the da Vinci technique. In addition, they reported that the rate of conversion to open surgery was 16% for the laparoscopic patients versus 0% among the da Vinci patients. This despite a greater probability for malignancy within the da Vinci group.
在其評論中,作者指出令他們驚訝的是,兩個隊列之間的手術時間顯示出顯著縮短,達文西技術較短超過75分鐘。此外,他們報告腹腔鏡病患轉為開腹手術的比率為16%,而達文西病患為0%。即便達文西組的惡性可能性更高亦然。
Also noteworthy was more pancreatic ductal adenocarcinomas were approached robotically -- 43% -- then laparoscopically, at 15%. Oncologic outcomes in these cases were superior for the robotic-assisted group, with higher rates of margin-negative resection and improved lymph node yield for both benign and malignant lesions.
同樣值得注意的是,胰管腺癌採用機器人方式處理的比例更高——43%——而腹腔鏡為15%。在這些病例中,機器人輔助組的腫瘤學結果更佳,無論良性或惡性病灶,皆有較高的切緣陰性切除率以及更佳的淋巴結清掃數量。
In their summaries, the authors wrote, and I quote, robotic distal pancreatectomies were equivalent to lab distal pancreatectomies in nearly all measures of outcomes and safety, but significantly reduced the risk of conversion to open resection despite a statistically greater probability of malignancy in the robotic cohort. We concluded that robotic assistance may broaden indications for minimally invasive pancreatectomy. End quote.
在其摘要中,作者寫道,我引用原文,機器人遠端胰臟切除術在幾乎所有結果與安全性衡量上,與腹腔鏡遠端胰臟切除術相當,但即使機器人隊列在統計上具有更高的惡性可能性,仍顯著降低轉為開腹切除的風險。我們的結論是,機器人輔助可能擴大微創胰臟切除術的適應症。引文結束。
This concludes my remarks, and I will now pass the time over to Calvin.
我的發言到此結束,接下來把時間交給Calvin。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you, Aleks. I will be providing you with an update to our financial forecast for 2013 on a GAAP basis. I will also provide estimates of significant noncash expenses.
謝謝你,Aleks。我將以GAAP基礎向各位提供我們2013年財務預測的最新更新。我也會提供重大非現金費用的估計。
Starting with procedures, on our last call we projected full-year 2013 procedures to grow towards the lower end of a range of between 20% and 23% from the base of approximately 450,000 procedures performed in 2012. Now, based upon moderating growth rates for US benign gynecologic procedures, we are adjusting our projection for full-year 2013 procedure growth to a range of between 15% and 18%.
先從手術量談起,在上次電話會議中,我們預估2013年全年手術量將在2012年約45萬例手術的基礎上,朝20%至23%區間的較低端成長。現在,基於美國良性婦科手術成長率趨緩,我們將2013年全年手術量成長預估調整為15%至18%的區間。
Moving to revenues, as has been discussed earlier on this call, capital sales of da Vinci systems are highly sensitive to changes in procedure growth patterns. Moderating procedure growth has led to increased capacity in our installed base. Given this sensitivity, it is challenging for us to forecast the number of systems we expect to sell in the second half of this year, so we have widened our guidance range. Given the significant portion of our revenue that is derived from system sales, we now expect total 2013 revenue to range from approximately flat to 7% growth compared to full-year 2012.
接著談營收,如同本次電話會議先前所討論,達文西系統的資本設備銷售對手術量成長型態的變化高度敏感。手術量成長趨緩導致我們已安裝基礎的產能增加。鑑於此敏感性,我們很難預測今年下半年預期可售出的系統數量,因此我們已擴大指引區間。由於我們相當大一部分營收來自系統銷售,我們目前預期2013年總營收相較2012年全年約為持平至成長7%的區間。
Turning to operating income, on our last call we forecast operating income to fall within a range of between 38% and 39% of net revenue. At this point, given our reduced revenue expectations, we are taking steps to scale back expenses. We do not intend to make short-term spending cuts in areas that would compromise our longer-term expansion strategies. As a result, we now anticipate full-year 2013 operating income to fall within a range of between 37% and 38% of revenue.
再談營業利益,在上次電話會議中,我們預測營業利益將落在淨營收的38%至39%區間。目前,鑑於我們降低的營收預期,我們正採取措施縮減費用規模。我們不打算在可能損及長期擴張策略的領域進行短期支出削減。因此,我們現在預期2013年全年營業利益將落在營收的37%至38%區間。
Now with regard to noncash stock compensation expenses -- on our last call we forecast 2013 total stock compensation to total between $184 million and $192 million for the year. Based upon our current stock price, we are reducing our forecast to a range of between $164 million and $172 million for the year.
接著就非現金股票薪酬費用而言——在上次電話會議中,我們預測2013年全年股票薪酬總額介於1.84億至1.92億美元。基於我們目前的股價,我們將預測下修至全年1.64億至1.72億美元的區間。
Timing of recognition should follow a quarterly pattern similar to 2012. We expect other income, which is comprised mostly of interest income, to total between $17 million and $19 million in 2013. With regard to income tax, our Q2 tax rate was 28.6% of pretax income. Our rate for the remainder of the year will likely be close to that level.
認列時點應會遵循與2012年相似的季度型態。我們預期其他收入(主要由利息收入構成)在2013年合計介於1,700萬至1,900萬美元。就所得稅而言,我們第二季稅率為稅前所得的28.6%。今年剩餘期間的稅率可能會接近該水準。
Our share count for calculating EPS in Q2 2013 was approximately 40.8 million shares. Directionally in Q3, our share count will likely modestly decline from the Q2 level. The actual share count will depend on several factors, including the magnitude and timing of share buybacks.
我們用於計算2013年第二季每股盈餘(EPS)的股數約為4,080萬股。就方向性而言,在第三季,我們的股數可能會較第二季水準小幅下降。實際股數將取決於多項因素,包括庫藏股回購的規模與時點。
That concludes our prepared remarks. We will now open the call to your questions.
我們事先準備的發言到此結束。接下來我們將開放各位提問。
Operator
Operator
(Operator Instructions). Ben Andrew, William Blair.
(接線員指示)。Ben Andrew,William Blair。
Ben Andrew - Analyst
Ben Andrew - Analyst
Wanted to follow up on a couple of points to start. And Gary, you had talked about the fact that system growth would likely be lumpy over the course of the coming quarters.
想先就幾點做個追問。Gary,你曾提到系統成長在接下來幾個季度可能會呈現不均勻的波動。
Can you give us some sense of what your inputs have been lately from the field and from customers, relative to how lumpy? And what the mix between new customers and existing customers is likely to look like going forward?
你能否讓我們了解一下,最近你們從前線與客戶那邊收到的回饋,關於波動程度大概會如何?以及未來新客戶與既有客戶之間的組合可能會是什麼樣子?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think the commentary is pretty much as we've outlined it for you. We see really an issue in the US of existing customers looking at capacity. We don't see existing customers walking away from the technology or the opportunity, but more a question of timing for them. So it feels more like a delay than otherwise.
我認為相關評論大致如同我們先前向各位說明的。我們看到美國這邊確實存在一個問題:既有客戶在評估產能。我們不認為既有客戶正在放棄這項技術或相關機會,而更多是他們在時點上的考量。因此感覺更像是延後,而非其他因素。
As we have said in the past, I think that capital sales are really driven by 3 underlying drivers. One of them is additional capacity in existing customers. One of them is technologies or new features that they would like to get. And the third are customers that are not yet da Vinci owners who are interested in engaging.
如同我們過去所說,我認為資本設備銷售主要由三個基本驅動因素所帶動。其中之一是既有客戶的額外產能需求。其二是他們希望取得的技術或新功能。其三則是尚未擁有達文西系統、但有興趣導入的客戶。
We've had good success with the new technologies that we have been bringing out, and so we see that as proceeding. I think the growth rate on benign gynecologic procedures has come in in the second quarter. It grew, but grew at a slower rate than we were expecting. And there's just a multiplier effect there on capacity. And so the capacity constraints in existing accounts will take some quarters to work out.
我們在推出的新技術方面取得了不錯的成果,因此我們認為這部分會持續推進。我認為良性婦科手術的成長率在第二季有所放緩。它仍在成長,但成長速度低於我們的預期。而這會對產能產生乘數效應。因此,既有客戶帳戶中的產能限制將需要幾個季度才能消化。
Ben Andrew - Analyst
Ben Andrew - Analyst
And Gary, can you maybe give us some comments, or maybe perhaps Aleks on this, about any correlation between the volume of benign GYN cases and physician visits? Because we've heard some noise back and forth about flattish or even sometimes declining patient volumes overall.
Gary,你能否就良性婦科(GYN)病例量與醫師門診就診次數之間的相關性,給我們一些評論?或者也請Aleks談談?因為我們聽到一些來回的雜音,說整體病患量大致持平,甚至有時在下降。
Does that appear to be part of it? Is maybe hysterectomy being utilized less frequently? Any other things like that around the procedure growth? Because obviously a big change in hysterectomy growth has kind of happened here in the last couple of quarters.
這看起來是否是其中一部分原因?是否子宮切除術的使用頻率正在降低?在手術量成長方面,還有其他類似的因素嗎?因為很明顯,過去幾個季度子宮切除術的成長出現了相當大的變化。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think in terms of total in-patient admissions as a whole and then people coming in seeking -- women coming in seeking hysterectomy, as you know, the inpatient admission data broadly lags for a while. So we get at that by more or less the same way you do, by talking to our customers, by looking at survey data, and trying and look at other analysis.
我認為,就整體住院收治總量,以及女性前來就醫尋求——女性前來尋求子宮切除術而言,如你所知,住院收治數據通常會延遲一段時間才反映出來。因此我們大致上是用和你們相同的方法來掌握:與客戶交流、查看調查數據,並嘗試做其他分析。
It's clear that in the first quarter, total inpatient admissions were lower than people had expected them, and in some cases, in some institutions, negative. As the total in Q2, we are hearing mixed feedback on total.
很明顯,在第一季,整體住院收治量低於人們的預期,而且在某些情況下、某些機構甚至是負成長。至於第二季的總量,我們聽到的回饋則是好壞參半。
For hysterectomy as a whole, our customers are seeing a pressure both in Q1 and in Q2. Quantifying that in Q2 is tough, just because the data lags. And so qualitatively we've seen some pressure there.
就子宮切除術整體而言,我們的客戶在第一季與第二季都看到壓力。要量化第二季的情況很困難,主要是因為數據有滯後。因此從質性角度來看,我們確實看到一些壓力。
And then there were some things that are just hard for us to handicap in terms of Intuitive-specific events and their impact on benign hyst. Things like the MCS notification are just harder for us to quantify what that impact was.
另外,也有一些事情在我們評估(handicap)直覺(Intuitive)特定事件及其對良性子宮切除術的影響時,確實很難判斷。例如MCS通知這類事件,我們更難量化其影響到底有多大。
Ben Andrew - Analyst
Ben Andrew - Analyst
Sure. And then Calvin, very briefly on the procedure guidance, the 15% to 18%, does that assume that benign hysterectomy grows sequentially in the back half versus the first half? I know you have got some big year-over-year comparisons there as well, so maybe a different answer versus year on year.
了解。另外Calvin,關於手術量指引15%到18%,非常簡短地問一下:這是否假設下半年良性子宮切除術的序列成長(sequentially)會高於上半年?我知道你們也面臨一些很大的年對年比較基期,所以答案可能會不同於年對年的解讀。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Yes, I think when you look at the overall guidance and the revised range, we are talking about your general surgery performing well and in line with our earlier guidance. And similarly on the urology side and international.
是的,我認為當你看整體指引與修訂後的區間時,我們談的是一般外科表現良好,且符合我們先前的指引。泌尿科以及國際市場也是類似情況。
So I think the change overall really is very much attributable to the benign gynecologic procedures in the US. And so I think we're still talking about growth. It's a moderating growth pattern, and the trajectory through the quarters ought to follow a similar pattern to what we have seen historically.
因此我認為整體變動主要可歸因於美國的良性婦科手術。我們仍然在談成長。只是成長型態趨於溫和,而各季度的走勢應該會遵循我們過去歷史上看到的類似模式。
Ben Andrew - Analyst
Ben Andrew - Analyst
Thank you.
謝謝。
Operator
Operator
Tao Levy, Wedbush Securities.
Tao Levy,Wedbush Securities。
Tao Levy - Analyst
Tao Levy - Analyst
On the warning letter that you received, it seems rather fast for the FDA to come in in June and then a few weeks later give you guys a warning letter. Can you maybe go into a little more details as to what they are looking for on that?
關於你們收到的警告信(warning letter),看起來FDA在6月進場後,幾週內就給你們警告信,速度似乎相當快。你能否更詳細說明他們在這方面主要在看什麼?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
The content of the letter is really a reflection of the content that was in the 43 Form that was issued in June. There were 4 observations. There are 2 mentions in the warning letter, which will become public. 2 mentions of things they'd like additional insight into.
信件內容其實反映了6月發出的43表(Form 43)中的內容。共有4項觀察事項。警告信中提到其中2點,且將會公開。另外有2點是他們希望我們提供更多說明與洞見的事項。
One of them had to do with procedure by which recalls are classified and their participation in that classification. That was the first bullet. And the other bullet they want additional information on has to do with user input and design elements, having to do with a particular product.
其中一項與召回(recall)如何分類的程序,以及他們在該分類中的參與方式有關。那是第一個要點。另一個他們希望補充資訊的要點,與使用者輸入與設計要素有關,涉及某一特定產品。
I think those are addressable. We are working on addressing them. I think we can address them quickly, and we will move on.
我認為這些都是可以處理的。我們正在著手處理。我認為我們可以很快解決,然後繼續往前。
Tao Levy - Analyst
Tao Levy - Analyst
Did the letter mention anything about having to come back and revisit the facility, or it's --?
信中有提到需要回來重新稽核該設施嗎?還是——?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
There is a mention that they will come back and audit specifically around recall classifications.
信中有提到他們會回來,並且會特別針對召回分類進行稽核。
Tao Levy - Analyst
Tao Levy - Analyst
And you also mentioned about Japan now not expecting any additional reimbursed procedures in the next cycle. What did the MHLW mention to you guys about that?
你也提到日本現在預期在下一個週期不會有任何新增可報銷(reimbursed)的手術。厚生勞動省(MHLW)對你們提到的原因是什麼?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
MHLW is working on guidance documentation for reimbursement -- more broadly than us -- for new technologies. That is outlining data requirements for what they'd like to see in Japan. Japan-specific data.
厚生勞動省正在制定關於報銷的指引文件——不僅針對我們——而是更廣泛地針對新技術。該文件正在概述他們希望在日本看到的數據要求。也就是日本特定(Japan-specific)的數據。
For prostatectomy we were able to use global data and had a good interaction with MHLW. Given current guidance, again, I think it's a class of products more broad than us. They're looking for additional data collection in Japan, specifically.
就前列腺切除術而言,我們能使用全球數據,並且與厚生勞動省有良好的互動。依照目前的指引,再次強調,這是一個比我們更廣泛的產品類別。他們正在尋求在日本境內進行額外的數據收集,特別是如此。
That's going to vary by procedure; their data requirements appear to vary by procedure having to do with the maturity of clinical data. And so it's not all locked down yet. We're continuing to work with the surgical societies, who in turn work with MHLW.
這會因手術而異;他們的數據要求似乎會依手術而不同,與臨床數據的成熟度有關。因此目前還沒有完全定案。我們會持續與外科醫學會合作,而醫學會也會與厚生勞動省合作。
But given the visibility we have on it now, it looks like there will be partial reimbursement followed by national reimbursement on a timeline that has to be decided based on their data requirements. As we get additional insight and understand it deeper, we will share that with you.
但就我們目前掌握的能見度來看,似乎會先有部分報銷,之後再轉為全國性報銷;其時間表將需依其數據要求來決定。當我們獲得更多洞見並更深入理解後,我們會與各位分享。
Tao Levy - Analyst
Tao Levy - Analyst
Lastly, the cadence on systems sales throughout the rest of the year -- is the pressure that we should model that's primarily just US-based? Is that the right way to think about it? Or do you see anything else in Europe, rest of the world, Japan, as well?
最後,關於今年剩餘時間系統銷售的節奏——我們應該建模的壓力主要是來自美國嗎?這樣理解對嗎?或者你們在歐洲、世界其他地區、日本等也看到其他情況?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I will start with a broad answer and let Marshall color it as well. In the US I think the dynamics that we saw in the second quarter may persist for the back half of the year.
我先給一個較概括的回答,也請Marshall再補充說明。在美國,我認為我們在第二季看到的動態可能會延續到下半年。
In terms of OUS, we are pleased with the progress we're making in Europe, but as you know, Europe can be really lumpy. And likewise in Japan. I think that Japan has had some boluses of pent-up demand, and what that looks like in future quarters is likely to not be stable. I don't think I would use the last couple of quarters to predict the future -- next quarters. Marshall, if you would --.
至於美國以外(OUS),我們對在歐洲取得的進展感到滿意,但如你所知,歐洲的表現可能非常不均勻、波動很大(lumpy)。日本也是如此。我認為日本曾出現一些被壓抑需求的集中釋放(boluses of pent-up demand),而未來幾季會呈現什麼樣貌,可能不會穩定。我不認為應該用最近幾個季度來預測未來——接下來幾季。Marshall,如果你願意——。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Yes. Specifically in Japan, we introduced Si at the beginning of the year, and I think that helped drive increased systems sales. And we don't see that level continuing. As Gary said, Europe will be lumpy. Particularly Q3 is the vacation period for them, and so historically we've seen lower sales in Europe in Q3.
是的。具體到日本,我們在年初導入了Si,我認為這有助於帶動系統銷售增加。但我們不認為那樣的水準會持續。如Gary所說,歐洲會比較波動。尤其第三季是他們的休假季,因此歷史上我們在歐洲第三季通常會看到較低的銷售。
Tao Levy - Analyst
Tao Levy - Analyst
Thanks.
謝謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛(Goldman Sachs)。
David Roman - Analyst
David Roman - Analyst
I wanted to -- Gary, I think in both your and Aleks's prepared remarks, you referenced the volume of data that continue to come out regarding the da Vinci system. But as you think about some of the headlines out there that have materialized in the past 6.5 months and the rising concerns, potentially around from payers as it relates to hysterectomies, to what extent have you started to rethink the need or potential need for a large-scale, randomized clinical trial to really definitively put a line in the sand on the value proposition of da Vinci that is a multi-center, multi-hundred patient clinical trial? Even if it is sponsored by the Company?
我想——Gary,我認為在你和Aleks的事先準備發言中,你們都提到了關於達文西(da Vinci)系統持續有大量數據發表。但當你們看待過去6個半月出現的一些新聞標題與日益升高的疑慮——可能也包括付款方(payers)在子宮切除術相關議題上的擔憂——你們在多大程度上開始重新思考:是否需要、或可能需要一項大規模的隨機臨床試驗,以真正明確地在達文西的價值主張上劃出界線;也就是一項多中心、數百名病患規模的臨床試驗?即便該試驗由公司贊助?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
That's a good question. Going forward, I think clearly large-scale studies are -- multi-institutional, multi-surgeons, are powerful and are important.
這是個好問題。展望未來,我認為很明顯,大規模研究——多機構、多位外科醫師——具有強大的說服力,而且很重要。
Speaking to the headlines a little bit, I think the headlines often confound the differences between complex procedures and simple ones, and the use of da Vinci as an alternative to open versus the use of da Vinci as an alternative to laparoscopy. I think there's a lot of very strong data for the use of da Vinci as an alternative to open surgery.
稍微回應一下媒體標題,我認為標題常常混淆了複雜手術與簡單手術之間的差異,也混淆了把達文西作為開腹手術替代方案,與把達文西作為腹腔鏡替代方案之間的差異。我認為,將達文西作為開腹手術替代方案,有大量非常有力的數據支持。
That said, going back to your comment, we are investing in large-scale studies. They're not always prospective randomized trials. Sometimes they are registries; sometimes they are occupational trials; sometimes they are prospective randomized. That depends a lot on the institutions that are doing them, and the nature of the data they already have, and the data they are collecting.
話雖如此,回到你的評論,我們正在投資於大規模研究。它們不一定都是前瞻性的隨機試驗。有時是登錄研究;有時是職業試驗;有時是前瞻性隨機研究。這在很大程度上取決於執行研究的機構、他們既有資料的性質,以及他們正在收集的資料。
But we are believers in big datasets. We think that matters. And over time you'll see more of that come out, both in hysterectomy and in other procedures.
但我們相信大型資料集。我們認為這很重要。隨著時間推移,你會看到更多這類成果發表,無論是在子宮切除術或其他手術上。
David Roman - Analyst
David Roman - Analyst
And maybe just on the system side, I certainly can appreciate that the slowing utilization or the slowing procedure volumes will impact the rate at which you sell systems, but it seems like a pretty fast drop-off in system placements relative to what is -- at least looks to be in the quarter -- a pretty modest slowing in procedure volumes.
也許就系統端而言,我當然能理解使用率放緩或手術量放緩會影響你們銷售系統的速度,但相較於——至少從本季看起來——手術量只是相當溫和地放緩,系統裝機量的下滑似乎非常快。
So is that -- am I reading that wrong if I say that there was already a lot of capacity out there of systems, and that a small tweak on the volume side is going to make a big impact on procedures? Or is that something that procedures worsened throughout the quarter, so the forward view is a little bit more cautious? Am I looking at that wrong?
所以如果我說——市場上其實已經有很多系統產能,而手術量端的小幅調整就會對手術造成很大影響——這樣解讀是不是不對?或者是本季內手術表現一路走弱,因此對未來的看法更為謹慎?我是不是看錯了?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I will separate it into two things. I'm going to take the second part first. The idea of did we see a softening in the back end of the quarter in terms of procedures and that, driving additional conservatism for the back half of the year, we did not see a strong falloff in procedures through the quarter. It wasn't that we got to the end, and procedures were really ramping down or anything like that in terms of rates.
我會把它分成兩件事。我先回答第二部分。關於我們是否在本季後段看到手術量走軟,進而讓我們對下半年更保守——我們並沒有看到本季內手術量明顯下滑。並不是到了季末,手術量在增速上真的大幅降溫之類的情況。
In terms of sensitivity, we came out of a strong fourth quarter of 2012, both in procedures and in systems. We saw some mixed dynamics in Q1 across the industry, us included, in terms of procedure volumes and in-patient admissions. And that benign hysterectomy for da Vinci growth rate really struggled to gain traction again in Q2. And I think that has added up to the sensitivity you're seeing and systems.
就敏感度而言,我們在2012年第四季表現強勁,無論是手術量還是系統。在第一季,整個產業(包括我們)在手術量與住院收治方面出現一些複雜且不一的動態。而達文西用於良性子宮切除(benign hysterectomy)的成長率在第二季確實很難再次取得動能。我認為這些因素累積起來,就造成你在系統端看到的敏感度。
I do think because systems are used for hundreds of procedures a year, and we're doing a fair number of procedures in the US that are benign -- but on hysterectomy procedures, there is the sensitivity that gets you to the capital number.
我確實認為,因為一套系統一年可用於數百台手術,而我們在美國也做了相當多屬於良性的手術——但在子宮切除手術上,確實存在那種敏感度,會把你帶到資本設備數字上。
David Roman - Analyst
David Roman - Analyst
Okay, that's helpful. And maybe lastly, on the guide, the flat to up 7% total revenue guidance for the year, just roughly looking at it, it seems as though you've taken a pretty conservative approach with respect to systems. It almost looks like you're extrapolating second-quarter trends and close to flatlining them through the balance of the year.
好的,這很有幫助。最後可能再問一下指引:全年總營收指引為持平到成長7%,粗略看起來,你們在系統方面採取了相當保守的做法。看起來幾乎是把第二季的趨勢外推,並在今年剩餘期間讓它接近持平。
So is that guidance meant to reflect the degree of uncertainty that might exist in both the capital markets as well as the timing of any correlation to slowing procedure volumes and slowing systems? That this is a view based on what you know today, and taking that forward, and that gives you some room on the overall performance of the business?
所以這個指引是否意在反映可能存在的不確定性——包括資本市場,以及手術量放緩與系統放緩之間任何相關性的時間點?也就是說,這是基於你們今天所掌握的資訊所做的看法,並將其往前推演,從而在整體業務表現上保留一些緩衝空間?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
David, our wider range in the revenue guidance does reflect the slower growth in da Vinci procedures. And really the uncertainty in the trend in dVH. Our underlying assumptions -- we assume roughly flat system utilization for the back half of the year, with the reduced growth assumptions on procedures, and the rest basically falls through. Again, as we discussed, the capital sales are highly sensitive to changes of procedure growth trends. And our guidance does assume materially fewer system sales in the second half of 2013 than the first.
David,我們營收指引區間較寬,確實反映了達文西手術量成長放緩。以及dVH趨勢的不確定性。我們的基本假設——我們假設下半年系統使用率大致持平,在手術量成長假設下修的情況下,其餘項目基本上就順勢反映。再次如我們所討論,資本設備銷售對手術量成長趨勢的變化高度敏感。而我們的指引也假設2013年下半年的系統銷售量將明顯少於上半年。
And a couple of other points on guidance while we're on the topic. We talk a lot about system ASPs. It's probably likely the second half system ASPs may be modestly lower than the first half, based on a higher proportion of sales that may involve trade-ins with the lower volumes. And then secondly, the second-half instrument and accessory revenue per procedure will probably also directionally be a bit lower than we saw in the first half, just based upon fewer stocking orders associated with the lower system sales.
另外在談到指引時再補充幾點。我們常談系統ASP(平均售價)。下半年系統ASP很可能會比上半年略低,原因是銷量較低時,可能涉及以舊換新(trade-in)的銷售占比更高。第二,下半年每台手術的器械與配件收入,方向上也可能會比上半年略低,主要是因為系統銷售較少,相關的補庫存訂單也會較少。
David Roman - Analyst
David Roman - Analyst
Okay. That is extremely helpful. Thank you.
好的。這非常有幫助。謝謝。
Operator
Operator
Amit Hazan, SunTrust.
Amit Hazan,SunTrust。
Amit Hazan - Analyst
Amit Hazan - Analyst
Just one question on the dVH side. One of the reasons you noted for weakness was the move of hysterectomy from the inpatient to the outpatient setting. But the data shows pretty clearly that this has been an ongoing things for years now, maybe about 5% or so a year consistently for a long time. So I'm wondering, what has really changed now, particularly this quarter, for you to have noted that beyond that already existing long-term trend?
我只有一個關於dVH的問題。你們提到疲弱的原因之一,是子宮切除從住院轉到門診。但數據相當清楚顯示,這其實多年來一直在發生,可能長期以來每年大約穩定5%左右。所以我想問的是,現在到底改變了什麼——特別是本季——讓你們在既有的長期趨勢之外,特別提出這點?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think there are a couple of underlying dynamics in the dVH space, and actually pulling them apart and putting numbers on them is very, very tough. One of them has been we've seen over recent quarters a pressure by payers on the use of hysterectomy as a whole. And we're hearing that back through our surgeon channels -- what it takes to authorize a hysterectomy and conservative medical management before that. We're also seeing payer policies towards driving them into the ambulatory settings versus inpatient settings.
我認為在dVH領域有幾個底層動態,而要把它們拆開並量化其影響其實非常、非常困難。其中之一是,近幾季我們看到付款方(payers)對整體子宮切除的使用施加壓力。我們也透過外科醫師渠道聽到回饋——包括核准子宮切除需要什麼條件,以及在此之前更保守的醫療管理。我們也看到付款方政策傾向於把手術導向門診場域,而非住院場域。
After that, the deductible dynamics and other macroeconomic trends, and then some Intuitive-specific dynamics around negative press and/or MCS notification, and you have got a set of things that can be contributors. Sorting exactly which is which in real time is very tough for us to do. It really is going to be survey data and retrospective analysis to figure out which of those is dominant. Some of them are increasing trends; some of them seem to be episodic trends.
此外還有自付額(deductible)相關動態與其他總體經濟趨勢,再加上一些Intuitive自身相關的動態,例如負面報導和/或MCS通知,於是就形成一組可能的影響因素。要在即時狀態下精確分辨哪個因素造成哪個影響,對我們來說非常困難。真正要弄清楚哪個因素占主導,可能需要調查數據與事後回溯分析。其中有些是上升中的趨勢;有些看起來則是偶發性的趨勢。
Amit Hazan - Analyst
Amit Hazan - Analyst
Okay. And then back to the systems side, I want to maybe touch on the deferral versus cancellation. Again, I think you guys were using the word deferral in your preannouncement press release.
好的。再回到系統端,我想談一下延期(deferral)與取消(cancellation)。我記得你們在預先公告的新聞稿中用的是「延期」這個詞。
Can you talk a little bit about the systems that maybe you were close to closing and didn't that were deferred because of the lower trajectory of expected growth for procedures, and whether you were hearing in large part that that was a deferral, and not necessarily cancellation and a move away from the technology? And are we talking virtually pretty much all of the units that fell into that bucket, or were there some that you feel were cancellation, and they were really moving away from your technology?
你能否談談那些原本接近成交但最後沒有成交的系統——因為預期手術量成長軌跡較低而被延期——以及你們聽到的主要是延期,而不一定是取消、也不是轉而放棄這項技術?我們談的是幾乎所有落入這個類別的台數嗎?還是有一些你們認為屬於取消,且他們確實是在遠離你們的技術?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
The pipeline entering the quarter, as we commented 3 months ago, was strong. But as you know, capital sales tend to be back-ended. So it wasn't until the end of the quarter that things started to drop off.
進入本季度時的銷售管線,如同我們在3個月前所評論的,是很強勁的。但如你所知,資本設備銷售往往會集中在季度後段。因此直到季度末,情況才開始下滑。
The reasons that we were given for systems falling off included things like inability to get financing, just additional levels of approval required within hospital systems. So it just felt like a harder environment from an economic perspective.
我們被告知系統案子流失的原因包括:無法取得融資、以及醫院體系內部需要額外的核准層級等。所以從經濟面來看,整體環境確實更艱難。
It did feel like a number of them were pushed off. Now, we see them being pushed off. Do they ultimately get done is really hard to predict. And we don't know if someone was hesitant to buy because of hospital dynamics, or concerns about the economy; whether they will still have those concerns for a quarter or two out; or whether those will go away, and capacities will catch up such that they buy.
確實感覺有不少案子被往後延。現在,我們看到它們正在被延後。它們最終是否會成交其實很難預測。而且我們也不知道,有人猶豫購買是因為醫院內部動態,或是對經濟的擔憂;這些擔憂在接下來一兩個季度是否仍會存在;或是會消退,產能追上後就會購買。
So it's really hard for us to predict which ones will come back and which ones will not. But the initial commentary that we're getting from hospitals was they were pushing them off.
所以我們很難預測哪些會回來、哪些不會。但我們從醫院端得到的初步回饋是,他們正在把這些案子往後推。
Amit Hazan - Analyst
Amit Hazan - Analyst
Okay. And just one final one for me on utilization. I think you mentioned you are assuming flat utilization in the back half. I'm just wondering, as we kind of start to think about general surgery, and especially cholecystectomy in there being a shorter procedure, whether we should be considering utilization for systems starting to go up a little bit more than it has been in historical trend?
了解。我最後一個問題是關於使用率。我想你提到你們假設下半年使用率持平。我只是想問,當我們開始思考一般外科,尤其是膽囊切除術屬於較短的手術時,我們是否應該考慮系統的使用率可能會比歷史趨勢再上升一些?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
It's a great point. As choles and other simpler procedures get done, they are faster. They are also -- tend to be more schedule-able. A benign disease patient can schedule into a slot, often, better or easier than in the case of a malignant disease.
這是個很好的觀點。當膽囊切除以及其他較簡單的手術增加時,它們執行得更快。而且它們也——通常更容易排程。良性疾病患者往往能更好或更容易地排進某個時段;相較之下,惡性疾病的情況就不一定。
So if that becomes material and bigger, I think that utilization may well go up. And I think ultimately that is a good thing for hospitals and a good thing for us. But it can create some uncertainty in terms of predicting where utilization ought to settle.
所以如果這部分變得重要且占比更大,我認為使用率很可能會上升。而我認為最終這對醫院是好事,對我們也是好事。但它確實會在預測使用率應該落在哪個水準上帶來一些不確定性。
Now things like, just to add a point, colorectal procedures that are also growing are complex, longer general surgery procedures and cancer procedures. So you have both of those dynamics going on at once. And so the mix change is the thing you have to predict to get to utilization, and that is how Calvin arrived at his guidance on it.
另外補充一點,像是也在成長的結直腸手術,屬於複雜、時間更長的一般外科手術與癌症手術。所以你同時會看到這兩種動態。因此,為了推估使用率,你必須預測的是手術組合的變化,而這也就是Calvin如何得出他對使用率的指引。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Yes. The trends have been, over the last few years, gradual growth. Low/mid single-digit percentage growth in utilization per system. There are almost 2,800 systems out there now, and they are all at the various stages of adoption. So my point is it's a large sample size, and that metric historically has moved very gradually in direction.
是的。過去幾年的趨勢是逐步成長。每套系統的使用率呈現低到中個位數百分比的成長。目前外面大約有2,800套系統,而且它們都處於不同的採用階段。所以我的重點是,這是一個很大的樣本數,而這個指標在歷史上一直是非常緩慢地朝某個方向變動。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
And just speaking for the long term, looking out all of the quarters, higher utilization is ultimately great for the hospitals. They get a good return on their investment, and it is great for the Company. So over time if it heads that way, then you will adjust.
從長期來看,放眼所有季度,更高的使用率最終對醫院非常有利。他們能獲得良好的投資報酬,對公司也非常好。所以隨著時間推移如果朝那個方向發展,你們就會做出調整。
Amit Hazan - Analyst
Amit Hazan - Analyst
Thanks, guys.
謝謝,各位。
Operator
Operator
David Lewis, Morgan Stanley.
David Lewis,摩根士丹利。
Jon Demchick - Analyst
Jon Demchick - Analyst
This is actually Jon Demchick in for David. Thanks for taking the question. So you gave some numbers on the magnitude of growth for your dVP in the quarter, but I didn't really hear, I guess, anything that specific towards dVH. So I was wondering if you could give, maybe, additional color on the magnitude for malignant or benign.
其實我是代替David的Jon Demchick。謝謝讓我提問。你們提供了本季度dVP成長幅度的一些數字,但我沒有聽到對dVH有什麼特別具體的說明。所以我想請問你們是否能就惡性或良性手術的成長幅度提供更多說明?
And if not, if you could also maybe discuss how you're thinking about some of those pressures, if they are maybe more temporary? Or if you think that they are more permanent or structural, and maybe the total addressable market that you've previously discussed maybe needs to come down a bit?
如果不方便的話,也請你們談談你們如何看待其中一些壓力:它們可能比較偏短期?還是你們認為它們更偏長期或結構性,並且你們先前討論過的總可服務市場(TAM)可能需要下修一些?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
I don't think we are going to give specific percentage growth rates in the hysterectomy here, but I think we were on a certain trajectory, I think, through 2012, and then it was a noticeable change in the growth rate in Q1 that was continued out into Q2. And when we look at our guidance, I think we are projecting out our growth rates at that lower trend.
我想我們不會在這裡提供子宮切除術的具體百分比成長率,但我認為我們在2012年之前大致沿著某個軌跡前進,而在第一季成長率出現了明顯變化,並延續到第二季。當我們看我們的指引時,我認為我們是以較低的趨勢來外推我們的成長率。
Aleks Cukic - VP of Strategic Planning
Aleks Cukic - VP of Strategic Planning
Yes, and as far as the addressable market, our -- again, what we have created is really a construct for the way we think about the procedures that we can access. We talk about -- in the case of dVH, it started with the complex, beginning with malignant endometrial cervical cancers, et cetera. And then into the complex benign. And we ultimately are going after what is open surgery.
是的,至於可服務市場,我們——再說一次,我們建立的其實是一個架構,用來思考我們能夠切入的手術類別。我們談到——以dVH為例,一開始是從複雜手術切入,從惡性的子宮內膜癌、子宮頸癌等開始。接著延伸到複雜的良性手術。而我們最終要切入的是開腹手術。
There may be some intersection between laparoscopic and so on, but really the primary target -- we still stand by that. We believe that is our target market. But what we have really realized is that as you get to the back half of these adoption curves, accessing those procedures with the same approach as you did on the front half of it is difficult. In other words, they don't consolidate the same way at the same pace.
可能會與腹腔鏡等有一些交集,但主要目標——我們仍然堅持那一點。我們相信那就是我們的目標市場。但我們真正意識到的是,當你走到這些採用曲線的後半段時,用你在前半段所採取的同樣方式去切入那些手術會很困難。換句話說,它們不會以相同的方式、相同的速度被集中(整合)。
So we feel strongly about the opportunity still being there and fruitful, but the timing of it on the back end is going to be difficult to predict. And therein lies the challenge that you saw in the first couple of quarters, and the effect that it had on systems.
所以我們仍然非常看好這個機會依舊存在且具成果,但在後段的時間點會很難預測。而這正是你在前兩個季度看到的挑戰,以及它對系統所造成的影響。
Jon Demchick - Analyst
Jon Demchick - Analyst
Thank you. Very helpful. And thinking more on the dVH side, also, will the dVH outlook maybe impact any hiring that is going on on the procedure side for general surgery? Or maybe affect the balance of just reps you have in access in both areas?
謝謝。非常有幫助。另外再從dVH的角度思考,dVH的展望是否可能影響你們在一般外科手術端的招募?或是影響你們在兩個領域之間配置可觸及的業務代表的平衡?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
As we think about opportunity, we look at it in terms of procedure growth regionally. So we look out at the US and the various regions and see what opportunity and penetration levels look like.
在思考機會時,我們會以各地區的手術量成長來看。因此我們會放眼全美各個區域,看看機會與滲透率大概是什麼樣子。
And they are non-uniform. It's not that the whole country is all at the same level of adoption. As adoption is deep in some areas for gynecology, that frees resources to pursue general surgery and other things. And so that's really how we are directing our sales force.
而且它們並不一致。不是全國各地都處於相同的採用水準。當某些地區在婦科的採用已經很深時,就能釋放資源去推進一般外科與其他領域。所以我們就是用這種方式來引導我們的銷售團隊。
Jon Demchick - Analyst
Jon Demchick - Analyst
And just one quick follow-up on the buyback authorization from March. I was just wondering if you could give any additional color on your thoughts toward the capital deployment and maybe timing.
另外快速追問一下3月的庫藏股回購授權。我想請問你們是否能就資本配置的想法以及可能的時點提供更多說明?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
It will be consistent with what we've said in the past. We'll look for the right opportunity to buy back shares. So looking for discontinuities in the stock price from the market. We have it authorized, and we intend to use it appropriately.
這會與我們過去所說的一致。我們會尋找合適的機會回購股票。也就是尋找股價相對於市場出現不連續(偏離)的時點。我們已取得授權,並且打算適當地使用它。
Jon Demchick - Analyst
Jon Demchick - Analyst
Thank you very much.
非常感謝。
Operator
Operator
Tycho Peterson, JPMorgan.
Tycho Peterson,摩根大通(JPMorgan)。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
First one, just on the general road map here for general surgery, can you talk a little bit about how sustainable you think the demand you are seeing in chole is right now? Are you seeing centers trial and then either ramp up, or -- what is the dynamic like there?
第一個問題,關於一般外科的整體路線圖,您能否談談您目前在膽囊(chole)方面看到的需求,您認為其可持續性如何?您是否看到一些中心先試行,然後再逐步擴大規模,或是——那裡的動態大概是怎樣?
And then can you also talk on bariatric and maybe some of these other opportunities in general surgery beyond chole and LAR, APR?
另外,您也能談談減重手術(bariatric),以及在一般外科中,除了膽囊(chole)與 LAR、APR 之外,其他一些機會嗎?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
On Single-Site cholecystectomy we've seen a good stick rate. In some ways a better stick rate than past procedures in terms of early experiences. And we've seen great growth out of some centers.
在單孔膽囊切除術(Single-Site cholecystectomy)方面,我們看到很好的持續採用率。在某些方面,就早期經驗而言,其持續採用率甚至比過去的手術更好。而且我們也看到一些中心帶來了很強勁的成長。
One of the exciting things about Single-Site cholecystectomy is that, number one, it is a procedure where surgeons can see high volume. So when they move, they get a lot of experience quickly. So the early part of that experience has been good.
單孔膽囊切除術令人振奮的一點是,第一,它是一種外科醫師可以看到高量(high volume)的手術。因此當他們開始導入時,能很快累積大量經驗。所以那段早期經驗一直都很不錯。
Having said that, there are absolutely some surgeons and there are absolutely some institutions who will not participate. There are some folks who believe in the value proposition and see the benefits it's bringing, and bringing to them its patients. We've had some centers have great growth in their admissions. But there are some who are on the sidelines and may stay on the sidelines. So I think it's going to split the field for some time.
話雖如此,確實有一些外科醫師,也確實有一些機構不會參與。有些人相信其價值主張,並看到它帶來的效益,以及帶給他們病人的效益。我們也看到有些中心的收治量(admissions)成長非常好。但也有一些仍在觀望,且可能會一直觀望下去。所以我認為這會在一段時間內讓市場出現分化。
How far it penetrates and how long -- I think that remains to be seen. I think there's a segment of patients that value it. I think there's a segment of surgeons who value it and who are gaining experience rapidly. But trying to call where the end is is not something we can do.
它能滲透到多深、以及會持續多久——我認為這仍有待觀察。我認為有一部分病人重視它。我也認為有一部分外科醫師重視它,並且正在快速累積經驗。但要去判斷最終會走到哪裡,這不是我們能做的事。
Aleks Cukic - VP of Strategic Planning
Aleks Cukic - VP of Strategic Planning
And with respect to the broader category that you outlined, and I think there's really two things to think about, or two ways to think about it. One is the absolute contribution of the individual procedure. So, for example, on a distal pancreatectomy or on a liver procedure, a spleen procedure, esophageal, they are going to contribute in the form of INE.
至於您提到的更廣泛類別,我認為其實有兩件事可以思考,或兩種思考方式。其一是單一手術本身的絕對貢獻。例如,遠端胰臟切除術(distal pancreatectomy)或肝臟手術、脾臟手術、食道手術,它們將以 INE 的形式做出貢獻。
But really, the hidden power there is the combination of strength from the surgeons that are performing a lot of the benign operations coupled with the strength of the surgeons who are seeing demand in things like colorectal, distal pancreatectomy, collectively getting together into the system purchasing suite or decision is also pretty powerful.
但真正隱藏的力量在於:大量執行良性手術的外科醫師所帶來的實力,結合那些在結直腸、遠端胰臟切除術等領域看到需求的外科醫師的實力;當他們共同在系統採購套件或決策上聚合起來時,也會非常有力。
So we don't really per se value them as one for one. I think the broader you go between malignant and cancer -- I should say malignant and benign -- the more strength you see in terms of placing systems out of that particular vertical, which we saw in gynecology and we saw in neurology, as well.
所以我們並不會把它們視為一對一的價值。我認為你在惡性與癌症——我應該說惡性與良性——之間涵蓋得越廣,你在該垂直領域之外推動系統裝機(placing systems)時就會看到越多的力量;我們在婦科與神經科也都看到了同樣的情況。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Tycho, we will give you one last follow-up here.
Tycho,我們再給你最後一個追問。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Just on Japan, can you talk about how the growth trajectory is going to change in the absence of the new procedures? And you alluded to the fact that they are looking for Japan-specific data, so you probably won't get the reimbursement code, but is that a definitive decision at this point that you won't get it?
關於日本,您能談談在沒有新手術項目的情況下,成長軌跡將如何改變嗎?另外您提到他們在尋找日本特定的數據,所以您可能拿不到給付代碼(reimbursement code),但目前是否已經是明確的決定:你們不會拿到?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
It is not definitive, but the conversation is ongoing. And per our statements, we think that broad approvals across multiple procedures are unlikely.
目前還不是定案,但相關對話仍在進行中。而依照我們的說法,我們認為跨多項手術的廣泛核准不太可能。
I can describe the process. What the growth rate looks like, I think, is hard to predict. Process-wise, we will submit data for the surgical societies. They will in turn work with MHLW. MHLW may require them to solicit and collect data in Japan. That may involve a partial reimbursement for certain number of centers. And if so, then that will start the process of data collection for a group of hospitals in Japan. How many and how many procedures concurrently, we don't have resolution on yet. But as I said before, as we get closer to it, we will share it with you.
我可以描述一下流程。至於成長率會是什麼樣子,我認為很難預測。在流程方面,我們會向外科學會提交資料。他們接著會與厚生勞動省(MHLW)合作。厚生勞動省可能會要求他們在日本徵詢並蒐集資料。這可能會涉及對特定數量中心提供部分給付。若是如此,那就會啟動在日本一組醫院的資料蒐集流程。至於會有多少家、以及同時涵蓋多少項手術,我們目前還沒有定論。但如我先前所說,等我們更接近時,我們會與各位分享。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay, thank you.
好的,謝謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Okay. That was our last question.
好的。這是我們最後一個問題。
I'd like to close with a letter we received this week from a surgeon and a medical director at one of the US academic centers. We talk about our finances and cash flow and so on, but it sort of takes us back to what the value of our products is.
我想以本週我們收到的一封信作結,這封信來自美國某所學術中心的一位外科醫師與一位醫療主任。我們談論財務、現金流等等,但這封信讓我們回到一個問題:我們產品的價值究竟是什麼。
And so this came from a surgeon and medical director. Quote, the work you are doing is touching patients' lives. It is healing them and getting them better.
因此,這封信來自一位外科醫師與醫療主任。引述:你們正在做的工作正在觸及病人的生命。它正在治癒他們,讓他們變得更好。
You cannot put a price on curing someone of their cancer and doing it with minimal change to their life. It is priceless. Let that inspire you to go ahead and continue the innovation to lead surgery into the future.
你無法為治癒某人的癌症定價,並且是在對其生活造成最小改變的情況下完成。這是無價的。讓這件事激勵你們繼續前進、持續創新,引領外科走向未來。
Patients are your partners in this endeavor. Sure, everything can be refined and everything can be improved, but you only get one chance sometimes to cure someone of their cancer. Your technology has given me a step up in that pursuit. Companies that help us change patients' lives will survive and prosper. End quote.
病人是你們在這項努力中的夥伴。當然,一切都可以精進,一切都可以改善,但有時你只有一次機會去治癒某人的癌症。你們的技術讓我在這項追求上更進一步。能幫助我們改變病人生命的公司,將會生存並繁榮。引述結束。
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months.
今天的電話會議到此結束。感謝各位在這段非凡旅程中——為了改善外科手術——的參與與支持,我們期待在 3 個月後再次與各位交流。
Operator
Operator
Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference service. You may now disconnect.
各位女士、先生,今天的會議至此結束。感謝各位的參與,以及使用 AT&T Executive Teleconference 服務。您現在可以掛線。